Self-enhancement lateral flow immunoassay for COVID-19 diagnosis
Issued Date
2023-08-15
Resource Type
ISSN
09254005
Scopus ID
2-s2.0-85154047203
Journal Title
Sensors and Actuators B: Chemical
Volume
389
Rights Holder(s)
SCOPUS
Bibliographic Citation
Sensors and Actuators B: Chemical Vol.389 (2023)
Suggested Citation
Ruantip S., Pimpitak U., Rengpipat S., Pasomsub E., Seepiban C., Gajanandana O., Torvorapanit P., Hirankarn N., Jaru-ampornpan P., Siwamogsatham S., Pongpaibool P., Siwamogsatham S., Thongchul N., Chaiyo S. Self-enhancement lateral flow immunoassay for COVID-19 diagnosis. Sensors and Actuators B: Chemical Vol.389 (2023). doi:10.1016/j.snb.2023.133898 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/81332
Title
Self-enhancement lateral flow immunoassay for COVID-19 diagnosis
Author's Affiliation
Other Contributor(s)
Abstract
Equipment-free colorimetric-based lateral flow immunoassay (LFIA) is the most convenient and popular tool for various applications, including diagnostic tools requiring high sensitivity for the detection of pathogens. Thus, improvements and developments of LFIA are constantly being reported. Herein, we enriched the sensitivity of LFIA using the gold enhancement principle, emphasizing needlessly complicated apparatus, only one step for the strip test operation, and typical time incubation (15 min) process. Self-enhanced LFIA was then executed for subsequent flows by overlapping the additionally enhanced pad composed of gold ions and reducing agent on the conjugate pad and the sample pad. Self-enhanced LFIA was performed to detect SARS-CoV-2 antigens in saliva. The obtained result depicted that the achieved sensitivity was up to tenfold compared with that of conventional LFIA by visual measurements. The detection limits of self-enhanced LFIA detecting nucleocapsid protein antigens in the saliva sample was 0.50 and 0.10 ng/mL employed by naked eye detection and calibration curve-based calculation, respectively. When the proposed device was applied to 207 human saliva samples, the diagnostic performance presented a 96.10 % sensitivity and 99.23 % specificity. This self-enhanced LFIA could be implemented in large-scale production and demonstrates higher sensitivity with effortless use, which meets the requirements for point-of-care testing and on-field mass screening.